# Shanghai AbelZeta

Source: https://onco.cc/companies/shanghai-abelzeta/  
OnCo record `shanghai-abelzeta` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Shanghai AbelZeta is a China-based cell therapy company running 2 late-stage cancer trials in hepatocellular carcinoma and multiple myeloma.

## Summary

Shanghai AbelZeta, based in Shanghai, China, is a cell therapy company. AbelZeta Pharma is a global cell therapy company focused on discovering, developing and manufacturing CAR-T therapeutics for haematologic malignancies, inflammatory and immunological diseases, and solid tumours. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials in hepatocellular carcinoma and multiple myeloma. The largest, NCT06590246 (A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/Recurrent Hepatocellular Carcinoma (HCC)), plans to enrol 121 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Shanghai AbelZeta Ltd.
- Tags: ctgov-sponsor
- HQ: Shanghai
- Type: cell-therapy
- Website: https://www.abelzeta.com/

## Sources

- Official website: https://www.abelzeta.com/
- ClinicalTrials.gov: trials led by Shanghai AbelZeta: https://clinicaltrials.gov/search?lead=Shanghai%20AbelZeta%20Ltd.

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- trials: [A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma](https://onco.cc/trials/nct05521802/), [A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/Recurrent Hepatocellular Carcinoma (HCC)](https://onco.cc/trials/nct06590246/)

---
JSON: https://onco.cc/api/v1/entities/shanghai-abelzeta.json